DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer.

DiaMedica Therapeutics has appointed Julie Krop, MD, as Chief Medical Officer, succeeding Lorianne Masuoka. Krop brings over 20 years of experience in biopharma, including rare disease programs and the approval of three drugs. She will lead DiaMedica's clinical development strategy for DM199, a potential treatment for preeclampsia and acute ischemic stroke.